Across 8 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Becton, Dickinson and Company news is Somewhat Bullish (+44)
on a scale from −100 to +100.
That is up 13 points from the previous 30 days (+31).
Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. Sells ...
AI-generated analysis
Key insights
📈 Becton, Dickinson and Company reported quarterly revenue of $5.27 billion, beating analyst estimates of $5.11 billion by $160 million.
💰 The company posted earnings per share of $4.15, topping the consensus estimate of $4.07 by $0.08.
🔄 BDX authorized a new share repurchase plan allowing the buyback of up to 10 million shares or 3.6% of outstanding equity.
💵 The company declared a quarterly dividend of $1.06 per share, an increase from the previous quarter's $1.05 payout.
📉 CEO Thomas Polen Jr. sold 2,993 shares for $628,530 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 2.65%.
🏦 BlackRock Inc. increased its position in BDX by approximately $3.7 billion during the second quarter.
📈 State Street Corp boosted its holdings by 8.5%, adding over 1.1 million shares to its portfolio.
🔍 Zacks Research upgraded BDX from a 'hold' rating to a 'strong-buy' rating in late October.
🎯 The consensus analyst target price for BDX is $195.47, with Jefferies Financial Group setting a high target of $242.
📈 Bullish signals
📈Revenue grew 5.4% year-over-year to $5.27 billion, exceeding analyst consensus estimates of $5.11 billion.
💰Earnings per share reached $4.15, beating the expected $4.07 by $0.08, demonstrating strong operational execution.
🔄The company authorized a new share repurchase program for up to 10 million shares, signaling management confidence in the stock's valuation.
💵Becton, Dickinson and Company increased its quarterly dividend to $1.06 per share from the previous $1.05.
🏦Major institutional investors including BlackRock, State Street, and First Eagle significantly increased their holdings in the second quarter.
🔍Zacks Research upgraded the stock to a 'strong-buy' rating following the strong quarterly earnings beat.
📉 Risk factors
📉The CEO sold 2,993 shares worth $628,530, representing a 2.65% reduction in his personal stake, though executed under a pre-arranged trading plan.
📉Barclays initiated coverage with an 'underweight' rating and set a price objective of $165, which is below the current market price.
Article
Becton, Dickinson and Company (NYSE:BDX) reported strong quarterly financial results for the period ending in late October, with revenue reaching $5.27 billion, a 5.4% year-over-year increase that beat analyst consensus estimates of $5.11 billion. The company posted earnings per share of $4.15, surpassing the expected $4.07, while maintaining a net margin of 4.52% and a return on equity of 14.79%. This performance highlights the medical instruments supplier's ability to grow revenue and profitability in its core healthcare markets.
Following the earnings release, the company announced a new share repurchase plan authorizing the buyback of up to 10 million shares, representing approximately 3.6% of its outstanding equity. Additionally, BDX declared a quarterly dividend of $1.06 per share, payable on December 31st to shareholders of record by December 10th. This marks an increase from the previous quarterly dividend of $1.05, reflecting a commitment to returning capital to investors despite a payout ratio exceeding 100%.
Institutional investor sentiment remains robust, with major funds like BlackRock, State Street, and First Eagle increasing their stakes in the second quarter. Analyst consensus is moderately bullish, with an average target price of $195.47 and recent upgrades from Zacks Research to a 'strong-buy' rating. While CEO Thomas Polen Jr. sold shares under a pre-arranged plan, the broader market data suggests confidence in BDX's long-term trajectory.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Becton Dickinson and Company (BDX) reported strong third-quarter fiscal 2026 results, with revenue reaching USD 5.0 billion, representing a 5.4% year-over-year increase. The company's adjusted earnings per share stood at USD 3.23, significantly outpacing the GAAP diluted EPS of USD 1.64 due to non-recurring items. This financial performance helped push the stock price to USD 188.13 on September 1, 2026, positioning it near its yearly high of USD 193.07.
The company continues to focus on its core medical technology business, which includes consumables, devices, and diagnostics. BDX maintains a consistent dividend policy with a quarterly payout of USD 1.05, set for payment on September 30, 2026. With a market capitalization of approximately USD 51.84 billion, the stock remains a significant component of the S&P 500 within the Health Care sector.
Analysts and investors are noting the substantial gap between adjusted and GAAP earnings, highlighting that non-recurring items still influence the reported bottom line. Despite this, the revenue crossing the USD 5 billion threshold and the solid year-over-year growth suggest continued operational strength in the medical instruments and supplies industry.
📊 Stock traded at USD 188.13 near its 52-week high.
💵 Quarterly dividend declared at USD 1.05 for Sept 30 payment.
🔍 Adjusted earnings exceeded GAAP by USD 1.59 per share.
📈 Becton Dickinson reported Q3 fiscal 2026 revenue of USD 5.0 billion, marking a 5.4% increase compared to the same period last year.
💰 The company achieved an adjusted EPS of USD 3.23 for the quarter, significantly higher than the GAAP diluted EPS of USD 1.64.
📊 Stock price reached USD 188.13 on September 1, 2026, trading just below its 52-week high of USD 193.07.
💵 BDX declared a quarterly dividend of USD 1.05 with a record date of September 9, 2026 and payment on September 30, 2026.
🏢 The company operates in the Health Care sector under the Medical Instruments and Supplies industry within the S&P 500.
📉 Revenue growth was driven by core segments including consumables, devices, and diagnostics.
🔍 Adjusted earnings exceeded GAAP earnings by USD 1.59 per share due to non-recurring items affecting the bottom line.
Bullish Signals
Revenue grew 5.4% YoY to $5.0B in Q3 fiscal 2026.
Risk Factors
Non-recurring items cause adjusted EPS (USD 3.23) to exceed GAAP diluted EPS (USD 1.64).
Stock traded 2.5% below its 52-week high, showing lack of immediate momentum.
Bullish Signals
Becton Dickinson achieved a robust 5.4% year-over-year revenue increase in Q3 fiscal 2026, reaching USD 5.0 billion.
The company reported an adjusted EPS of USD 3.23, demonstrating strong underlying profitability despite GAAP figures being lower.
Stock price climbed to USD 188.13, trading near its yearly high and showing resilience in the Health Care sector.
BDX maintains a consistent commitment to shareholders with a quarterly dividend of USD 1.05 scheduled for payment.
Risk Factors
The significant gap between adjusted EPS (USD 3.23) and GAAP diluted EPS (USD 1.64) indicates that non-recurring items continue to impact the reported earnings line.
Stock price traded 2.5% below its 52-week high, suggesting some caution or lack of immediate momentum despite strong quarterly results.
Becton Dickinson (BDX) shares have gained momentum following a clinical trial milestone for its GalaFLEX LITE Scaffold in breast revision surgery, which triggered a planned interim analysis. The stock recently posted a 30-day return of 12.54% and a 90-day return of 28.82%, reflecting investor reaction to recent progress, leadership changes, and upcoming conference appearances.
Analysts at Simply Wall St estimate Becton Dickinson's fair value at approximately $189.58, which is nearly identical to the current trading price of $189.52. This valuation relies on assumptions regarding earnings power, margins, and capital returns that are expected to reshape the company's profit mix following a strategic transformation.
The company is undergoing a significant structural change with the pending separation of its Biosciences and Diagnostic Solutions businesses. This move aims to transform Becton Dickinson into a pure-play medical technology leader with a consumables-heavy portfolio representing over 90% of revenue, which should enable higher cash flow predictability and margin improvement.
To support this growth strategy, the company plans to execute aggressive share buybacks directly intended to drive earnings per share (EPS) growth. However, investors must weigh these positive catalysts against potential risks including tariff and trade pressures, as well as execution challenges associated with successfully separating the business units.
🏥 STANCE trial reaches enrollment milestone for GalaFLEX LITE Scaffold.
📈 Stock gained 12.54% in 30 days and 28.82% in 90 days.
💰 Fair value of $189.58 matches current trading price of $189.52.
🔀 Executing separation to become pure-play medical technology leader.
⚠️ Risks include tariffs, trade pressures, and split execution challenges.
🏥 Becton Dickinson's STANCE clinical trial for the GalaFLEX LITE Scaffold in breast revision surgery has reached a first enrollment milestone, triggering a planned interim analysis.
📈 The stock recently posted a 30-day share price return of 12.54% and a 90-day return of 28.82%, indicating renewed investor momentum.
💰 Analysts estimate Becton Dickinson's fair value at $189.58, which is almost identical to the current trading price of $189.52.
🔀 The company is executing a pending separation of its Biosciences and Diagnostic Solutions businesses to become a pure-play medical technology leader.
📊 This strategic split aims to create a consumables-heavy portfolio representing over 90% of revenue, targeting higher cash flow predictability and margin improvement.
💸 Aggressive share buybacks are anticipated to directly support earnings per share (EPS) growth for the company.
⚠️ Investors face potential risks from ongoing tariff and trade pressures affecting the medical technology sector.
🛠️ Execution risk remains a key consideration regarding the successful separation of the Biosciences and Diagnostic Solutions units.
Bullish Signals
Becton Dickinson's STANCE clinical trial for the GalaFLEX LITE Scaffold has reached a first enrollment milestone, triggering a planned interim analysis that validates product progress.
The company is executing a pending separation of its Biosciences and Diagnostic Solutions businesses to transform into a pure-play medical technology leader with a consumables-heavy portfolio exceeding 90% of revenue.
This strategic restructuring is expected to enable higher cash flow predictability and margin improvement for the company.
Anticipated aggressive share buybacks are described as directly supporting earnings per share (EPS) growth.
Risk Factors
Investors must weigh potential risks from ongoing tariff and trade pressures affecting the company's operations.
Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. sold 4,152 shares of company stock on August 13th for a total transaction value of $768,120. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, resulting in a 3.63% decrease in his personal position. Following the trade, the CEO retains ownership of 110,163 shares, valued at approximately $20.38 million.
The company recently reported strong quarterly financial results announced on August 6th. Becton, Dickinson and Company posted earnings per share (EPS) of $3.23, beating the consensus estimate of $3.14, while revenue reached $4.98 billion against an expectation of $4.89 billion. The firm achieved a net margin of 4.52% and a return on equity of 14.79%, with quarterly revenue growing 5.4% year-over-year.
Analyst sentiment remains mixed regarding the stock's valuation and future targets. While Jefferies Financial Group reissued a 'buy' rating with a $210 target, other major firms like Goldman Sachs and Bank of America have lowered their price objectives to neutral or hold ratings. The consensus price target stands at $185.67, slightly above the current trading price, reflecting varied outlooks on the medical technology sector.
The company maintains a consistent dividend policy with an upcoming payment of $1.05 per share scheduled for September 30th to shareholders of record on September 9th. This represents a yield of 2.3% and an annualized dividend of $4.20. Institutional ownership remains high at 86.97%, with significant activity from investors like Jupiter Topco LLC and Man Group plc adding to their stakes during the second quarter.
📉 CEO sold 4,152 shares for $768,120 on August 13th.
💰 Q2 EPS hit $3.23, beating estimates by $0.09.
📈 Revenue reached $4.98 billion, up 5.4% year-over-year.
💵 Net margin is 4.52% with ROE of 14.79%.
📅 Dividend of $1.05 per share pays September 30th.
📉 CEO Thomas Polen, Jr. sold 4,152 shares for $768,120 on August 13th under a pre-arranged Rule 10b5-1 trading plan.
💰 The company reported Q2 EPS of $3.23, beating the consensus estimate of $3.14 by $0.09.
📈 Revenue for the quarter reached $4.98 billion, surpassing the $4.89 billion consensus and growing 5.4% year-over-year.
💵 The firm achieved a net margin of 4.52% and a return on equity of 14.79% during the reported period.
📅 A quarterly dividend of $1.05 per share is scheduled for payment on September 30th to shareholders of record on September 9th.
🎯 Analyst Jefferies Financial Group reissued a 'buy' rating with a price target of $210.00 on August 6th.
📉 Goldman Sachs lowered its price objective from $156.00 to $150.00 and maintained a neutral rating in May.
🏦 Bank of America reduced its price target from $177.00 to $170.00 in a June research note.
📊 The stock currently trades at a PEG ratio of 12.82 with a market capitalization of $50.47 billion.
🏛️ Institutional ownership stands at 86.97%, led by significant additions from Jupiter Topco LLC and Man Group plc.
Bullish Signals
EPS beat at $3.23 vs $3.14 consensus.
Revenue hit $4.98 billion, matching estimates.
Quarterly revenue grew 5.4% year-over-year.
Jefferies raised price target to $210.
Dividend yield stands at 2.3%.
Institutions added $75.9 million to positions.
Risk Factors
Goldman Sachs lowered target from $156 to $150.
Bank of America cut target from $177 to $170.
High PEG ratio of 12.82 suggests overvaluation.
Price below 50-day average of $157.84 and 200-day average of $161.70.
Bullish Signals
The company beat quarterly earnings expectations with EPS of $3.23 versus the consensus of $3.14.
Revenue of $4.98 billion exceeded analyst estimates of $4.98 billion, demonstrating strong top-line performance.
Quarterly revenue grew 5.4% compared to the same quarter last year, indicating sustained business growth.
Jefferies Financial Group reissued a 'buy' rating with an ambitious price target of $210.00.
The company maintains a consistent dividend yield of 2.3% with a payout history supporting shareholder returns.
Major institutional investors like Jupiter Topco LLC added approximately $75.9 million to their positions in the second quarter.
Risk Factors
Goldman Sachs lowered its price objective from $156.00 to $150.00, signaling a more cautious outlook.
Bank of America reduced its price target from $177.00 to $170.00 in June, reflecting potential valuation concerns.
The stock carries a high PEG ratio of 12.82, suggesting the market may be pricing in significant future growth expectations that are difficult to meet.
The current trading price is below the 50-day moving average of $157.84 and the 200-day moving average of $161.70, indicating short-term weakness.
BD (Becton, Dickinson and Company) announced the successful completion of enrollment in the PREVENT clinical trial, a significant milestone for its advanced tissue regeneration strategy. The study evaluates Phasix™ Mesh for the prevention of incisional hernias following abdominal surgery, addressing a critical unmet need where no approved prophylactic products currently exist.
The large-scale randomized study enrolled 477 patients across 32 sites in the United States and Europe. It represents the first major trial assessing prophylactic reinforcement using a resorbable mesh for this specific indication, aiming to generate robust clinical evidence for patients at high risk of post-surgical complications.
Led by Rian Seger, worldwide president of Surgery at BD, the initiative seeks to extend the impact of regenerative technologies into new areas of patient care. Patients will be followed through a primary endpoint at 24 months, with longer-term safety evaluations planned for up to five years.
Following the completion of primary assessments, data from the study is expected to support a planned submission to the U.S. Food and Drug Administration. This development aligns with BD's broader strategy of driving innovation across medical essentials and interventional solutions to optimize clinical operations and improve patient outcomes.
🏥 BD completed enrollment in PREVENT trial for Phasix™ Mesh.
📊 Study enrolled 477 patients across 32 sites globally.
🔬 First randomized study on resorbable mesh for hernia prevention.
⏳ Patients followed to 24-month primary endpoint with 5-year plan.
💡 Addresses unmet need as no approved products exist yet.
🏥 BD successfully completed enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for incisional hernia prevention.
📊 The study enrolled 477 patients across 32 sites in the United States and Europe.
🔬 This is the first large, randomized study assessing prophylactic reinforcement using a resorbable mesh for this indication.
⏳ Patients will be followed through a primary endpoint at 24 months with long-term follow-up planned for five years.
📝 Data from the study is expected to support a future submission to the U.S. Food and Drug Administration.
💡 The trial addresses a significant unmet need as no products are currently approved for incisional hernia prevention.
👤 Rian Seger, worldwide president of Surgery at BD, highlighted the commitment to extending advanced tissue regeneration into new patient care areas.
Bullish Signals
Completed PREVENT trial enrollment at 32 sites.
Validates Phasix™ Mesh as first-in-class resorbable solution.
Targets unmet need for incisional hernia prevention.
Strong operational execution in U.S. and Europe.
Bullish Signals
BD achieved a major milestone by completing enrollment in the PREVENT trial, validating its advanced tissue regeneration strategy and expansion efforts.
The study targets a significant unmet medical need for incisional hernia prevention, positioning Phasix™ Mesh as a potential first-in-class resorbable mesh solution.
Successful enrollment across 32 sites demonstrates strong clinical interest and operational execution capability in both the U.S. and Europe.
The trial aims to generate robust clinical evidence that could broaden the role of regenerative technologies, potentially creating new market opportunities.
Becton, Dickinson and Company (BDX) shares surged 5.4% on Tuesday, July 28, 2026, closing at $167.58 with trading volume of 634,513 shares. The significant gain occurred as the medical device sector experienced a broad-based rally, with BDX outperforming major peers including Abbott Laboratories, Stryker, and Intuitive Surgical.
The coordinated advance across the sector suggests investors are rotating into healthcare equipment makers driven by general optimism rather than specific company developments for Becton Dickinson. This synchronized movement indicates that institutional investors may be adjusting portfolio allocations or reacting to emerging sector-wide tailwinds affecting medical instruments and supplies.
📈 Becton Dickinson stock jumped 5.4% to $167.58 on July 28, 2026.
🏥 Market leader valued at $46.2 billion in medical instruments and supplies.
🔄 Sector peers like Abbott Laboratories also posted substantial gains today.
📉 BDX outpaced all major sector peers with strong trading volume.
💼 Rally driven by broad healthcare equipment sector optimism and rotation.
📈 Becton, Dickinson and Company stock jumped 5.4% on July 28, 2026, closing at $167.58.
📊 Trading volume reached 634,513 shares during the session reflecting active investor participation.
🏥 The company is a $46.2 billion market leader in medical instruments and supplies.
🔄 Sector peers including Abbott Laboratories and Stryker also posted substantial gains.
📉 BDX outpaced all major sector peers, suggesting potential catch-up buying or outsized momentum.
🔍 The rally appears driven by broad sector optimism rather than specific company news.
💼 Investors are rotating into healthcare equipment makers amid renewed appetite for the sector.
Bullish Signals
BDX shares gained 5.4%, outperforming major peers.
Closed at $167.58 with strong trading volume.
$46.2 billion maker positioned for sector growth.
Bullish Signals
BDX shares gained 5.4%, outperforming all major sector peers including Abbott Laboratories (4.2%) and Stryker (3.9%).
The company closed at $167.58 with healthy trading volume of 634,513 shares indicating strong market interest.
As a $46.2 billion medical instruments maker, BDX is well-positioned to benefit from broad sector-wide optimism and tailwinds.
Piper Sandler analyst Jason Bednar raised his price target for Becton, Dickinson and Company (BDX) to $205 from $190 while maintaining a Neutral rating. The firm noted that BD is transitioning its Life Sciences segment to Waters starting in Q1 2026 and has updated its financial models accordingly, though estimates still include the legacy unit during the transition period.
In January, Becton Dickinson announced an $110 million investment to expand production of prefillable syringes at its Columbus, Nebraska facility. This capital expenditure aims to support faster delivery of biologic and GLP-1 drugs by strengthening pharmaceutical manufacturing capabilities in the U.S., with initial supply expected by mid-2026.
The expansion includes $100 million dedicated to establishing Neopak Glass Prefillable Syringe production and upgrading existing lines to meet rising global demand for advanced injectables. An additional $10 million will enhance cannula manufacturing, projects collectively expected to create approximately 120 new jobs and improve supply resilience within the Pharmaceutical Systems business.
📈 Analyst raises Becton Dickinson price target to $205 with Neutral rating.
🔄 Life Sciences segment transitions to Waters starting Q1 2026.
💰 Company announces $110 million investment for syringe production expansion.
🏭 Columbus facility adds Neopak lines by mid-2026 and creates 120 jobs.
💉 Expansion targets biologic and GLP-1 drug delivery supply resilience.
📈 Piper Sandler analyst Jason Bednar raised Becton Dickinson's price target to $205 from $190 while maintaining a Neutral rating.
🔄 The company is transitioning its Life Sciences segment to Waters beginning in Q1 2026, prompting updates to financial models.
💰 Becton Dickinson announced an $110 million investment to expand prefillable syringe production capabilities.
🏭 The Columbus, Nebraska facility will see new Neopak Glass Prefillable Syringe production lines established by mid-2026.
👷 The expansion projects are expected to create approximately 120 new jobs at the Columbus site.
💉 The investment targets strengthening pharmaceutical manufacturing for biologic and GLP-1 drug delivery.
📈 $100 million of the capital is specifically allocated to establishing Neopak syringe production capacity.
🔧 An additional $10 million will be directed toward enhancing cannula manufacturing operations.
🌍 The upgrades aim to address rising global demand for advanced injectable medical products.
🛡️ The expansion is designed to improve supply resilience within the Pharmaceutical Systems business unit.
Bullish Signals
Analyst Jason Bednar raised price target to $205.
$110 million capital investment expands manufacturing capacity.
Columbus facility expansion creates approximately 120 new jobs.
New capabilities support biologic and GLP-1 drug delivery.
Upgrades address rising global demand for injectable products.
Risk Factors
Life Sciences segment transitions to Waters, causing short-term restructuring risks.
Analyst Jason Bednar from Piper Sandler increased the price target to $205, reflecting confidence in the company's outlook despite a Neutral rating.
The $110 million capital investment demonstrates strong commitment to expanding manufacturing capacity for high-demand pharmaceutical products.
The Columbus facility expansion will create approximately 120 new jobs, signaling robust growth in the Pharmaceutical Systems division.
New production capabilities are specifically targeted at supporting the growing market for biologic and GLP-1 drug delivery systems.
Upgrades to existing lines and cannula manufacturing address rising global demand for advanced injectable products.
Risk Factors
The Life Sciences segment is set to transition to Waters in the coming weeks, which may introduce short-term restructuring complexities or reporting changes.
Piper Sandler maintained a Neutral rating, suggesting that while the investment is positive, it does not yet constitute a strong buy signal for the stock.
Institutional investors have made mixed moves in Becton, Dickinson and Company (BDX) during the first quarter of 2026. Bartlett & CO. Wealth Management LLC reduced its stake by 30.6%, selling 8,514 shares to hold a remaining position worth $2.8 million. Conversely, several other firms increased their exposure, with Assetmark Inc. boosting its holdings by 31.2% to own over 355,000 shares valued at $55.9 million, and John G Ullman & Associates raising its stake nearly 100%.
Analyst sentiment remains largely neutral to cautious regarding the medical technology giant. Weiss Ratings downgraded BDX from a 'hold' to a 'sell', while TD Cowen and Piper Sandler lowered their price targets to $163 and $159 respectively, citing valuation concerns. However, Barclays maintained an 'overweight' rating with a slightly raised target of $204. The consensus rating among seven buy-side analysts is currently 'Hold' with an average price target of $180.29.
Financial metrics indicate the stock is trading below its 200-day moving average of $166.39, having recently hit a 12-month low of $127.59. The company recently paid a quarterly dividend of $1.05 per share, resulting in an annualized yield of 2.7%. However, the payout ratio stands at 106.33%, suggesting the dividend is being funded from cash reserves rather than current earnings. Insider trading activity shows recent sales by CEO Thomas E. Polen, Jr. and EVP Michael David Garrison under pre-arranged plans.
Becton, Dickinson and Company operates as a global leader in medical devices, life sciences research tools, and interventional technologies. Its product portfolio includes single-use items like syringes and needles, as well as complex systems for infusion therapy and vascular access. Despite the mixed institutional activity and neutral analyst consensus, the company maintains a significant market capitalization of $43.57 billion with a PEG ratio of 11.19.
📈 Assetmark Inc. increased stake by 31.2%, owning $55.9 million total.
⚠️ Dividend payout ratio is 106.33%, exceeding current earnings per share.
📉 CEO sold 2,764 shares for $404,511 under Rule 10b5-1 plan.
🏥 Operations span medical devices, life sciences tools, and interventional tech.
📉 Bartlett & CO. Wealth Management LLC reduced its BDX holdings by 30.6% in Q1, selling 8,514 shares while retaining a $2.8 million position.
📈 Assetmark Inc. significantly increased its stake by 31.2%, purchasing an additional 84,539 shares to own a total of 355,449 shares valued at $55.9 million.
📉 John G Ullman & Associates raised its position by 98.2% in the first quarter, adding 2,675 shares to its portfolio.
📉 Weiss Ratings downgraded Becton, Dickinson and Company from a 'hold (c-)' to a 'sell (d+)' rating on May 11th.
📉 TD Cowen lowered its price target from $189.00 to $163.00 and maintained a 'hold' rating in late April.
📉 Piper Sandler reduced its price target to $159.00 with a 'neutral' rating following an April 17th report.
📉 Barclays raised its price target to $204.00 and assigned an 'overweight' rating on May 11th.
💰 BDX paid a quarterly dividend of $1.05 per share, yielding 2.7% annually based on the record date of June 9th.
⚠️ The company's dividend payout ratio is 106.33%, indicating the dividend exceeds current earnings per share.
📉 CEO Thomas E. Polen, Jr. sold 2,764 shares for $404,511 on June 1st under a Rule 10b5-1 trading plan.
📉 EVP Michael David Garrison sold 1,100 shares for $160,226 on June 24th, reducing his personal stake by 7.71%.
📊 The stock trades at a PEG ratio of 11.19 with a market capitalization of $43.57 billion.
📉 BDX shares opened at $158.14, trading below its 200-day simple moving average of $166.39.
🏥 The company's operations span medical devices, life sciences research tools, and interventional technologies.
📊 Institutional investors collectively own 86.97% of the company's outstanding stock.
Bullish Signals
Assetmark increased BDX investment by 31.2%, adding over $5 million.
Barclays raised price target to $204 with 'overweight' rating.
Market cap stands at $43.57 billion with 2.7% dividend yield.
Risk Factors
Weiss Ratings downgraded stock to sell (d+) rating.
Multiple analysts lowered price targets in recent months.
Dividend payout ratio of 106.33% is unsustainable.
Stock trading below $166.39 moving average and $127.59 low.
Bullish Signals
Assetmark Inc. significantly increased its investment in BDX by 31.2%, adding over $5 million to its position, signaling institutional confidence.
Barclays raised its price target to $204 and maintained an 'overweight' rating, suggesting potential upside from current levels.
The company maintains a substantial market capitalization of $43.57 billion and a strong dividend yield of 2.7%.
Risk Factors
Weiss Ratings downgraded the stock to a 'sell (d+)' rating, reflecting concerns about valuation or growth prospects.
Multiple analysts including TD Cowen, Piper Sandler, and Goldman Sachs lowered their price targets in recent months.
The dividend payout ratio of 106.33% indicates the company is paying out more than its current earnings, which may be unsustainable without cash reserves.
The stock is trading below its 200-day moving average of $166.39 and recently hit a 12-month low of $127.59.
D.A. Davidson & CO. increased its stake in Becton, Dickinson and Company (BDX) by 13.5% during the first quarter, adding 8,783 shares to a total holding of 73,877 shares valued at $11.6 million. Several other institutional investors also adjusted their positions, with Marshall Wace LLP significantly increasing its stake by 365.1% and United Bank growing its holdings by 23.9%, while hedge funds collectively own 86.97% of the company's stock.
BDX recently reported quarterly earnings that beat analyst expectations, posting $2.90 per share compared to a consensus of $2.77, with revenue reaching $4.71 billion, a 5.2% year-over-year increase. The company has set full-year 2026 guidance between $12.52 and $12.72 EPS, slightly above the average analyst prediction of $12.62. Analysts have issued mixed ratings, with an average target price of $180.29, though recent reports from Argus and Stifel Nicolaus lowered their price targets.
The company paid a quarterly dividend of $1.05 per share on June 30th, resulting in an annualized yield of 2.6%. However, the payout ratio stands at 106.33%, indicating dividends are currently exceeding earnings. Recent insider activity includes sales by CEO Thomas E. Polen, Jr. and EVP Michael David Garrison, who sold shares under pre-arranged Rule 10b5-1 trading plans, with insiders collectively reducing their holdings by approximately $765,000 in the last three months.
📈 D.A. Davidson increased BDX stake by 13.5% to 73,877 shares.
💰 Q4 EPS beat estimates at $2.90 with revenue growth of 5.2%.
🎯 FY 2026 EPS guidance set between $12.52 and $12.72.
⚠️ Dividend payout ratio is 106.33%, funded from cash reserves.
📉 Average analyst price target remains $180.29 despite recent drops.
📈 D.A. Davidson & CO. increased its BDX stake by 13.5% to 73,877 shares worth $11.6 million during Q1.
📊 Institutional investors like Marshall Wace LLP and United Bank significantly boosted their positions in the medical device supplier.
💰 Becton, Dickinson reported Q4 earnings of $2.90 EPS, beating estimates of $2.77 with revenue of $4.71 billion.
📈 Revenue grew 5.2% year-over-year to $4.71 billion, exceeding analyst expectations of $4.67 billion.
🎯 The company set FY 2026 EPS guidance between $12.52 and $12.72, slightly above the average analyst forecast.
💸 A quarterly dividend of $1.05 was paid on June 30th with an annualized yield of 2.6%.
⚠️ The payout ratio is 106.33%, meaning dividends are currently being funded from cash reserves rather than earnings.
📉 Argus lowered its price target to $180 and Stifel Nicolaus dropped theirs to $175, though the average analyst target remains $180.29.
👔 CEO Thomas E. Polen, Jr. sold 2,764 shares for $404,511 under a pre-arranged trading plan on June 1st.
📉 EVP Michael David Garrison sold 1,100 shares for $160,226 on June 24th as part of a Rule 10b5-1 plan.
🏦 Hedge funds and institutional investors own 86.97% of the company's outstanding stock.
📉 The stock trades at a PE ratio of 40.47 with a market capitalization of $44.05 billion.
Bullish Signals
EPS beat consensus at $2.90 vs $2.77.
Revenue grew 5.2% YoY to $4.71 billion.
Full-year 2026 EPS guidance set between $12.52-$12.72.
D.A. Davidson increased stake by 13.5% to 73,877 shares.
Marshall Wace added 25,022 shares valued at $5.49 million.
Risk Factors
Argus lowered target from $230 to $180.
Stifel dropped target from $215 to $175.
Goldman Sachs decreased target from $156 to $150.
Payout ratio is 106.33%, exceeding earnings per share.
Insiders sold 5,188 shares worth $765,120.
Bullish Signals
BDX reported quarterly earnings of $2.90 EPS, beating analyst consensus estimates of $2.77 by $0.13.
Revenue reached $4.71 billion, surpassing expectations of $4.67 billion and growing 5.2% year-over-year.
The company set full-year 2026 EPS guidance between $12.52 and $12.72, which is higher than the average analyst prediction of $12.62.
D.A. Davidson & CO. increased its stake by 13.5% to 73,877 shares, signaling continued institutional confidence.
Marshall Wace LLP significantly increased its position by 365.1%, adding 25,022 shares valued at $5.49 million.
United Bank grew its holdings by 23.9% to 5,149 shares, indicating broader institutional accumulation.
The company maintains a strong balance sheet with a debt-to-equity ratio of 0.62 and a current ratio of 0.94.
Risk Factors
Argus lowered its price target from $230 to $180 while maintaining a 'buy' rating, indicating potential downside risk.
Stifel Nicolaus dropped its price target from $215 to $175 and issued a neutral rating on the stock.
The Goldman Sachs Group decreased its target price from $156 to $150 with a 'neutral' rating.
The payout ratio is 106.33%, indicating that dividends are currently exceeding earnings per share.
CEO Thomas E. Polen, Jr. sold 2,764 shares for $404,511, reducing his personal stake by 2.45%.
EVP Michael David Garrison sold 1,100 shares for $160,226, decreasing his ownership by 7.71%.
Insiders collectively sold 5,188 shares worth $765,120 in the last three months, reducing their total ownership to 0.40%.
The article presents a bullish investment thesis on Becton, Dickinson and Company (BDX), arguing that the stock is currently mispriced following its strategic transformation. As of June 8, 2026, shares traded at $149.99 with a forward P/E of 11.21, which analysts suggest is disconnected from the company's mid-single-digit growth potential and recurring revenue streams.
In Q2 fiscal 2026, BDX reported continuing-operations revenue of $4.714 billion and adjusted diluted EPS of $2.90. The company raised its full-year adjusted EPS guidance to a range of $12.52–$12.72, signaling improved execution across core segments like diagnostics and life sciences.
Following the Waters transaction, which generated approximately $4.0 billion in net cash, management is prioritizing capital return through a $2.0 billion asset sale and repurchase (ASR) and an ongoing buyback authorization of roughly 4.2% of shares outstanding. The company is simplifying its reporting to focus on continuing operations, reducing noise from separation and restructuring charges.
The thesis concludes that BDX resembles a steady compounding medtech platform rather than a transition story, with upside driven by capital returns and potential multiple expansion toward normalized medtech multiples as earnings quality improves and volatility decreases.
📈 BDX shares at $149.99 with forward P/E of 11.21.
💰 Q2 revenue hit $4.714 billion and adjusted EPS $2.90.
🚀 Full-year adjusted EPS guidance raised to $12.52–$12.72.
💸 Waters deal generated $4.0 billion in net cash proceeds.
🔄 Prioritizing $2.0 billion asset sale alongside buybacks.
📈 Becton, Dickinson and Company (BDX) shares traded at $149.99 on June 8, 2026, with a forward P/E of 11.21.
💰 Q2 fiscal 2026 continuing-operations revenue reached $4.714 billion with adjusted diluted EPS of $2.90.
🚀 Management raised full-year fiscal 2026 adjusted EPS guidance to a range of $12.52–$12.72.
💸 The Waters transaction generated approximately $4.0 billion in net cash for the company.
🔄 A $2.0 billion asset sale and repurchase (ASR) is being prioritized alongside ongoing buybacks.
📉 Buyback authorization stands at approximately 4.2% of total shares outstanding.
🏥 The business spans medical technology franchises in diagnostics, life sciences, and high-margin consumables.
📊 Analysts view the current valuation as disconnected from mid-single-digit growth and recurring revenues.
🔍 The company is simplifying its reporting base to focus on continuing operations post-spin.
📈 Market multiples are expected to expand toward normalized levels if execution continues.
🛡️ Improved transparency and lower earnings volatility are cited as key drivers for future performance.
🏆 BDX is described as a steady compounding medtech platform rather than a transition story.
Bullish Signals
Raised FY2026 EPS guidance to $12.52–$12.72.
Generated $4.0B net cash from Waters transaction.
Executing $2.0B asset sale and ~4.2% buybacks.
Trading at forward P/E of 11.21.
Q2 FY2026 revenue hit $4.714B with $2.90 EPS.
Bullish Signals
BDX raised its fiscal 2026 adjusted EPS guidance to $12.52–$12.72, signaling strengthening execution across core segments.
The company generated approximately $4.0 billion in net cash from the Waters transaction, enabling significant capital return initiatives.
Management is executing a $2.0 billion asset sale and repurchase (ASR) combined with ongoing buybacks of ~4.2% of shares outstanding.
The stock trades at a forward P/E of 11.21, which analysts argue is disconnected from the company's durable recurring revenue streams and growth potential.
Continuing-operations revenue in Q2 fiscal 2026 reached $4.714 billion with adjusted diluted EPS of $2.90.
Institutional ownership of Becton, Dickinson and Company (BDX) saw notable shifts in the first quarter, led by Elevation Point Wealth Partners LLC trimming its stake by 77.8% to just 1,632 shares worth $257,000 after selling over 5,700 shares. Conversely, several other firms including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc. initiated or significantly increased their positions in the fourth quarter, collectively adding hundreds of thousands of dollars in value to their holdings.
Analyst sentiment remains mixed with a consensus 'Hold' rating and a target price of $180.29, though individual targets vary widely from $157 to $215. Wells Fargo raised its objective to $161 with an 'equal weight' rating, while Stifel Nicolaus cut its target to $175. The stock trades at a P/E ratio of 38.52 and recently paid a quarterly dividend of $1.05 per share, resulting in a yield of 2.8%.
Insider trading activity shows recent sales by top executives, including CEO Thomas E. Polen, Jr., who sold 2,764 shares for approximately $404,500 under a pre-arranged Rule 10b5-1 plan, and EVP Michael David Garrison, who sold 1,100 shares for roughly $160,000. These transactions represent small percentage decreases in their respective holdings but indicate continued liquidity among top management.
BDX operates as a global medical technology company with a market capitalization of $41.93 billion, producing single-use devices, infusion therapy solutions, and interventional technologies. The company maintains a debt-to-equity ratio of 0.62 and trades above its 50-day moving average but below its 200-day average, reflecting a neutral-to-slightly-bearish technical stance amidst stable operational fundamentals.
📉 Elevation Point Wealth reduced BDX holdings by 77.8% to $257,000 in Q1.
📈 Multiple institutions added stakes while analyst consensus remains 'Hold' at $180.29.
💰 Quarterly dividend of $1.05 yields 2.8% for record holders on June 9th.
👔 CEO and EVP sold shares totaling over $564,000 in early June.
🏢 Institutional investors control 86.97% with a market cap of $41.93 billion.
📉 Elevation Point Wealth Partners LLC reduced its BDX holdings by 77.8% in Q1, selling 5,705 shares to retain only 1,632 shares valued at $257,000.
📈 Multiple institutional investors including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc. added new stakes or significantly increased positions in Q4.
📊 Analyst consensus remains 'Hold' with a target price of $180.29, though Wells Fargo raised its objective to $161 while Stifel Nicolaus lowered it to $175.
💰 The company recently paid a quarterly dividend of $1.05 per share, yielding 2.8% for investors of record on June 9th.
👔 CEO Thomas E. Polen, Jr. sold 2,764 shares worth $404,511 in early June under a pre-arranged Rule 10b5-1 trading plan.
📉 EVP Michael David Garrison executed a sale of 1,100 shares for $160,226 on June 24th, reducing his position by 7.71%.
🏢 Total insider ownership stands at 0.40%, while institutional investors control 86.97% of the company's outstanding stock.
📈 BDX trades with a market cap of $41.93 billion and a P/E ratio of 38.52, currently priced between its 50-day and 200-day moving averages.
🔬 The medical technology giant manufactures single-use devices, infusion therapy solutions, and interventional technologies for healthcare institutions.
⚖️ Financial metrics show a debt-to-equity ratio of 0.62 and a dividend payout ratio of 106.33%, indicating the company is paying out slightly more than current earnings.
Bullish Signals
Major investors increased stakes in Q4 signaling confidence.
Wells Fargo raised price target to $161.00.
Strong balance sheet with debt-to-equity ratio of 0.62.
Consistent quarterly dividend yields 2.8%.
Risk Factors
Major fund cut position by 77.8% to $257,000.
Analyst price target lowered from $215.00 to $175.00.
Executives sold over $564,000 in shares last month.
Stock trades below 200-day moving average of $167.81.
Bullish Signals
Several institutional investors, including Steph & Co., SHP Wealth Management, and Prosperity Bancshares Inc., initiated or significantly increased their stakes in Q4, signaling continued confidence from new capital.
Wells Fargo & Company raised its price objective to $161.00 and maintained an 'equal weight' rating, suggesting stability in the stock's valuation.
The company maintains a strong balance sheet with a debt-to-equity ratio of 0.62 and has declared a consistent quarterly dividend yielding 2.8%.
Risk Factors
Elevation Point Wealth Partners LLC drastically reduced its position by 77.8% in Q1, trimming holdings to a mere $257,000 after selling over 5,700 shares.
Stifel Nicolaus cut its price objective from $215.00 to $175.00 and maintained a neutral stance, reflecting concerns about current valuation levels.
Recent insider sales by CEO Thomas E. Polen, Jr. and EVP Michael David Garrison total over $564,000 in June, which can be interpreted as executives taking profits at current price levels.
The stock trades below its 200-day simple moving average of $167.81, indicating a longer-term downtrend or lack of bullish momentum relative to historical averages.
Becton, Dickinson and Co. (BD) has announced the release of a new point-of-care test designed to detect antibodies in blood, confirming current or past exposure to COVID-19. Unlike competitors focusing solely on detecting the active virus, BD's assay targets serology to identify immune responses, which is crucial for understanding infection rates among asymptomatic populations and informing future public health strategies.
The new test can deliver results in as little as 15 minutes and does not require special equipment, making it suitable for use in laboratories or at the point of care. BD's Integrated Diagnostic Solutions division highlighted that this rapid serology test complements existing molecular diagnostics, helping clinicians rule out infection when combined with negative viral tests.
To accelerate this effort, BD has entered into an agreement with BioMedomics to add a rapid serology test to its portfolio and is collaborating with Henry Schein, leveraging the latter's extensive knowledge of the point-of-care test field. This strategic move aims to provide additional data on prior exposure to SARS-CoV-2, aiding researchers in characterizing the true occurrence of the disease across the population.
Financially, Becton Dickinson stock traded down less than 1% to $228.38 on Wednesday, maintaining a position within its 52-week range of $197.75 to $286.72. The consensus price target for the company stands at $270.62, while the article also provided context on competitor movements in the diagnostic testing sector.
🧬 BD launches new rapid antibody test for COVID-19 exposure.
⏱️ Results available in 15 minutes without special equipment needed.
🤝 Partners with BioMedomics and Henry Schein to expand testing.
📊 Helps identify asymptomatic infections and track true infection rates.
🎯 Stock trades at $228.38 with $270.62 analyst price target.
🧬 Becton, Dickinson and Co. (BD) has launched a new point-of-care test to detect antibodies indicating current or past exposure to COVID-19.
⏱️ The assay delivers results in as little as 15 minutes without requiring special equipment, suitable for lab or point-of-care settings.
🤝 BD announced an agreement with BioMedomics to augment its rapid serology testing capabilities.
🏥 The company is collaborating with Henry Schein to leverage the partner's extensive knowledge of the point-of-care test field.
📊 This new test helps clinicians identify asymptomatic infections and aids researchers in understanding true infection occurrence rates.
💰 Becton Dickinson stock traded down less than 1% to $228.38, trading within a 52-week range of $197.75 to $286.72.
🎯 The consensus price target for Becton Dickinson is set at $270.62 by analysts.
🔬 BD's approach focuses on serology rather than just detecting the active novel coronavirus like some competitors.
Bullish Signals
BD secures BioMedomics deal for rapid COVID-19 serology test.
New antibody test provides critical prior exposure data.
Henry Schein collaboration accelerates point-of-care test market adoption.
Bullish Signals
BD has secured a strategic agreement with BioMedomics to integrate a rapid serology test, expanding its diagnostic capabilities in the high-demand COVID-19 testing market.
The new antibody detection test provides critical data on prior exposure, which is essential for public health strategies and understanding asymptomatic infection rates.
Collaboration with Henry Schein leverages a major distributor's expertise in point-of-care tests, potentially accelerating market adoption of BD's new assay.
Institutional investors have significantly increased their stakes in Becton, Dickinson and Company (BDX) during the first and fourth quarters of 2026. Howe & Rusling Inc. raised its position by 32.8% to own 32,547 shares valued at $5.1 million, while major funds like Vanguard Group, Wellington Management, and Auto Owners Insurance Co also boosted their holdings substantially, with institutional ownership now standing at 86.97%.
Analyst sentiment remains mixed but generally stable, with a consensus rating of 'Hold' and an average price target of $181.00. Recent upgrades from Zacks Research and Barclays alongside price target increases from Evercore contrast with a downgrade from TD Cowen. The stock currently trades at a market cap of $43.56 billion with a P/E ratio of 40.02, trading above its 50-day moving average but below its 200-day average.
Financially, BDX reported strong quarterly results in May, beating earnings estimates with $2.90 EPS and revenue of $4.71 billion, representing a 5.2% year-over-year increase. The company has set full-year 2026 guidance between $12.52 and $12.72 per share. Additionally, the firm recently paid a quarterly dividend of $1.05 per share, yielding 2.7%, though the payout ratio is elevated at 106.33%.
Executive trading activity saw both EVP Michael David Garrison and CEO Thomas E. Polen, Jr. sell shares under pre-arranged Rule 10b5-1 plans in June. Garrison sold 1,100 shares for $160,226, while Polen sold 2,764 shares for $404,511. These transactions reduced their individual holdings slightly but were executed as part of established trading plans rather than immediate market reactions.
📈 Howe & Rusling Inc. increased BDX stake by 32.8% to 32,547 shares.
📈 Vanguard Group boosted holdings by 13.0% to 36.68 million shares.
📊 Q2 EPS of $2.90 beat consensus estimate of $2.77.
💰 Revenue reached $4.71 billion, up 5.2% year-over-year.
🎯 Consensus rating is 'Hold' with average price target of $181.
📈 Howe & Rusling Inc. increased its BDX stake by 32.8% to 32,547 shares worth $5.1 million in Q1.
📈 Vanguard Group boosted holdings by 13.0% to 36.68 million shares valued at $7.1 billion in Q4.
📈 Wellington Management and Auto Owners Insurance Co significantly increased stakes, with the latter adding over 40 million shares.
📊 BDX reported Q2 EPS of $2.90, beating the consensus estimate of $2.77 by $0.13.
💰 Revenue reached $4.71 billion, up 5.2% year-over-year against analyst expectations of $4.67 billion.
📅 The company set FY 2026 EPS guidance between $12.52 and $12.72.
💸 A quarterly dividend of $1.05 was paid on June 30th, resulting in a 2.7% yield.
📉 CEO Thomas E. Polen, Jr. sold 2,764 shares for $404,511 under a Rule 10b5-1 plan.
📉 EVP Michael David Garrison sold 1,100 shares for $160,226 under a pre-arranged trading plan.
🏦 Institutional investors own 86.97% of the company's outstanding stock.
🎯 The consensus analyst rating is 'Hold' with an average price target of $181.00.
📉 TD Cowen lowered its price target to $163.00 and assigned a 'Hold' rating in May.
Bullish Signals
EPS beat estimates by $0.13 at $2.90.
Revenue exceeded expectations at $4.71 billion.
Year-over-year revenue growth reached 5.2%.
Zacks upgraded stock from 'strong sell' to 'hold'.
Evercore raised price objective to $190.00.
Risk Factors
TD Cowen lowered price target to $163 and rated 'hold'.
Stock trades below 200-day moving average of $169.33.
Insiders sold 5,188 shares worth $765,120 in ninety days.
Dividend payout ratio is unsustainable at 106.3%.
Bullish Signals
BDX reported earnings per share of $2.90, which beat the consensus estimate of $2.77 by $0.13.
Revenue for the quarter was $4.71 billion, exceeding analyst expectations of $4.67 billion.
The company achieved a 5.2% year-over-year revenue growth compared to the same quarter last year.
Zacks Research upgraded the stock from a 'strong sell' rating to a 'hold' rating.
Evercore increased its price objective from $180.00 to $190.00.
Barlifted its target price from $202.00 to $204.00 and assigned an 'overweight' rating.
The company paid a quarterly dividend of $1.05, providing a 2.7% yield to shareholders.
Institutional ownership remains robust at 86.97%, indicating strong investor confidence.
Risk Factors
TD Cowen lowered its price target from $189.00 to $163.00 and assigned a 'hold' rating.
The stock is trading below its 200-day simple moving average of $169.33.
Corporate insiders sold a total of 5,188 shares valued at $765,120 over the last ninety days.
The dividend payout ratio is 106.33%, indicating the company is paying out more in dividends than its current earnings generate.
Becton Dickinson (BDX) has secured an Innovative Technology contract from Vizient for its BD CentroVena One Insertion System and is undergoing an FDA transition for SARS-CoV-2 testing products. Additionally, the company's status within the Russell index is shifting, which may influence trading patterns. These developments highlight a strategic pivot in Becton Dickinson's product portfolio and operational focus.
Despite a year-to-date share price decline of 22.37%, Becton Dickinson has delivered an 11.04% total shareholder return over the past year, indicating resilience against short-term selling pressure. Analysts suggest the stock trades at a discount to intrinsic value estimates and analyst targets, with a prevailing narrative valuing the fair price at $181.23 compared to the recent closing price of $151.33.
The core investment thesis centers on an upcoming business separation that will transform Becton Dickinson into a pure-play medical technology leader focused on consumables, which constitute over 90% of revenue. This restructuring is expected to enhance cash flow predictability and margins, supported by aggressive share buybacks designed to drive earnings per share growth.
Investors must weigh the potential rewards of this undervaluation against risks such as higher-than-expected tariff costs or operational drag from the business separation. The article concludes that while sentiment is mixed between risk concerns and optimism regarding future earnings power, the current valuation gap presents a potential opportunity for long-term investors.
🏥 BDX secured an Innovative Technology contract for its CentroVena One Insertion System.
📉 Shares dropped 22.37% YTD but delivered an 11.04% total shareholder return last year.
💰 Analysts value stock at $181.23, implying a 16.5% undervaluation versus recent close.
🔄 Pending separation will split off Biosciences and Diagnostic Solutions into a pure-play entity.
⚠️ Risks include tariffs, trade costs, and earnings drag from the business separation.
🏥 Becton Dickinson (BDX) secured an Innovative Technology contract from Vizient for its BD CentroVena One Insertion System.
🔬 The company is undergoing an FDA transition regarding its SARS-CoV-2 testing products.
📉 Shares are down 22.37% year-to-date but have generated an 11.04% total shareholder return over the last year.
💰 Analysts estimate a fair value of $181.23, suggesting the stock is undervalued by approximately 16.5% compared to the recent close of $151.33.
🔄 A pending business separation will split off Biosciences and Diagnostic Solutions, creating a pure-play medical technology entity.
📦 The restructured company will focus on a consumables-heavy portfolio representing over 90% of total revenue.
💸 Aggressive share buybacks are anticipated to support future earnings per share growth.
⚖️ The restructuring aims to improve cash flow predictability and overall profit margins.
📉 The stock currently trades about 23% below one intrinsic value estimate and 17% below analyst targets.
⚠️ Key risks include potential negative impacts from tariffs, trade costs, or earnings drag from the business separation.
Bullish Signals
BDX won Vizient Innovative Technology contract for BD CentroVena One.
Company transitioning SARS-CoV-2 testing products through FDA process.
BDX delivered 11.04% total shareholder return despite 22.37% YTD drop.
Analysts estimate fair value of $181.23 vs recent price of $151.33.
Separation creates pure-play medical tech leader with consumables over 90% revenue.
Risk Factors
Shares declined 22.37% year-to-date.
Stock trades 23% below intrinsic value estimate.
Tariff costs may weigh heavily on operations.
Business separation risks lasting earnings drag.
Bullish Signals
BDX has won a significant Innovative Technology contract from Vizient for its BD CentroVena One Insertion System.
The company is successfully transitioning its SARS-CoV-2 testing products through the FDA process.
Despite a 22.37% drop in share price year-to-date, BDX delivered an 11.04% total shareholder return over the past year.
Analysts view the stock as undervalued, with a fair value estimate of $181.23 versus a recent closing price of $151.33.
The upcoming separation of Biosciences and Diagnostic Solutions will transform BDX into a pure-play medical technology leader.
The new structure will feature a consumables-heavy portfolio exceeding 90% of revenue, enhancing cash flow stability.
Aggressive share buybacks are planned to directly support earnings per share growth.
The restructuring is expected to drive margin improvement and increase cash flow predictability.
AMI Asset Management Corp reduced its stake in Becton, Dickinson and Company (BDX) by 2.4% during the first quarter, selling 6,482 shares to hold 263,904 shares valued at $41.49 million. While AMI decreased its position, several other institutional investors including Steph & Co., SHP Wealth Management, Prosperity Bancshares Inc, and WPG Advisers LLC increased or initiated new positions in the medical instruments supplier during the fourth quarter.
Analyst sentiment remains mixed with a consensus 'Hold' rating and an average target price of $181.00. Major firms like Piper Sandler, Stifel Nicolaus, and TD Cowen recently lowered their price targets to between $159.00 and $175.00, while Weiss Ratings downgraded the stock to a 'sell' rating. Conversely, Barclays maintained an 'overweight' rating and slightly raised its target price to $204.00.
The company recently declared a quarterly dividend of $1.05 per share, payable on June 30th to shareholders of record on June 9th, resulting in a 2.7% yield. However, corporate insiders including CEO Thomas E. Polen, Jr. and EVP Michael David Garrison sold shares totaling over $965,000 in late May and early June under pre-arranged trading plans.
Financial metrics show BDX trading near its 50-day moving average with a market capitalization of $42.66 billion. The stock carries a high PE ratio of 39.19 and a payout ratio exceeding 100%, while maintaining a debt-to-equity ratio of 0.62. Institutional ownership stands at 86.97% as the company continues to focus on medical devices, life sciences research tools, and interventional technologies.
📉 AMI Asset Management sold 6,482 shares while keeping a $41.49M position.
📈 Steph & Co., SHP Wealth, and WPG Advisers increased their stakes in Q4.
📉 Weiss Ratings downgraded BDX to 'sell (d+)' with lower price targets from others.
💰 Quarterly dividend of $1.05/share offers a 2.7% yield payable June 30th.
📊 BDX trades at 39.19 PE ratio with $42.66B market cap and 86.97% institutional ownership.
📉 AMI Asset Management Corp reduced its BDX holdings by 2.4% in Q1, selling 6,482 shares while maintaining a $41.49 million position.
📈 Multiple other investors including Steph & Co., SHP Wealth Management, and WPG Advisers LLC increased their stakes in the fourth quarter.
📉 Weiss Ratings downgraded BDX to a 'sell (d+)' rating, while Piper Sandler, Stifel Nicolaus, and TD Cowen lowered price targets.
📈 Barclays maintained an 'overweight' rating and raised its price target to $204.00 amidst mixed analyst sentiment.
💰 The company declared a quarterly dividend of $1.05 per share with a 2.7% yield payable on June 30th.
📉 CEO Thomas E. Polen, Jr. and EVP Michael David Garrison sold shares totaling over $965,000 in recent transactions.
📊 BDX trades at a PE ratio of 39.19 with a market cap of $42.66 billion and institutional ownership of 86.97%.
⚖️ The company maintains a debt-to-equity ratio of 0.62 but operates with a payout ratio exceeding 100%.
Bullish Signals
Major investors increased or initiated BDX positions in Q4.
Barclays raised price target to $204 with overweight rating.
Quarterly dividend of $1.05 offers 2.7% yield.
Risk Factors
Weiss Ratings downgraded BDX to 'sell (d+)' rating.
Analysts lowered price targets between $159.00 and $175.00.
Insiders sold shares totaling over $965,000 recently.
High PE ratio of 39.19 and payout over 100%.
Bullish Signals
Several institutional investors, including Steph & Co., SHP Wealth Management, Prosperity Bancshares Inc, and WPG Advisers LLC, increased or initiated new positions in BDX during the fourth quarter.
Barclays maintained an 'overweight' rating and raised its price target to $204.00, indicating continued confidence in the company's long-term prospects.
The company declared a quarterly dividend of $1.05 per share, providing a 2.7% yield to shareholders.
Risk Factors
Weiss Ratings downgraded BDX from a 'hold' to a 'sell (d+)' rating, signaling concerns about the stock's current valuation or performance.
Major analysts including Piper Sandler, Stifel Nicolaus, and TD Cowen recently lowered their price targets to between $159.00 and $175.00.
Corporate insiders, including CEO Thomas E. Polen, Jr. and EVP Michael David Garrison, sold shares totaling over $965,000 in recent transactions under pre-arranged plans.
The stock carries a high PE ratio of 39.19 and a payout ratio exceeding 100%, which may limit future dividend growth or indicate stretched valuation.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical instruments and supplies with a market capitalization of $42.96 billion. Headquartered in Franklin Lakes, New Jersey, the company serves healthcare institutions, life science researchers, and the pharmaceutical industry. Currently trading at $155.92, the stock has shown stability with a recent price change of 0.03% within a 52-week range spanning from $135.42 to $185.39.
Analysts project a potential upside of 14% for BDX, supported by an average target price of $177.75 and a forward P/E ratio of 11.64, which suggests the stock is relatively undervalued compared to peers. The company demonstrates strong financial health with revenue growth of 5.20%, robust free cash flow exceeding $4.5 billion, and an earnings per share (EPS) of 5.72. Additionally, BDX offers a dividend yield of 2.69% with a payout ratio of 72.95%, providing reliable income for investors.
Technical indicators indicate that BDX is trading above its 50-day moving average and near its 200-day moving average, with an RSI of 55.75 suggesting the stock is neither overbought nor oversold. Analyst sentiment remains positive with six buy ratings and eight hold ratings, while no sell ratings are present. The strategic collaboration with ChemoGLO further underscores the company's commitment to innovation and safety within healthcare settings.
With a target price range between $150.00 and $225.00, BDX presents an opportunity for investors seeking long-term growth and stability in the healthcare sector. The combination of solid valuation metrics, strong cash generation, and strategic partnerships positions the company well for future expansion. Investors considering a diversified portfolio may find BDX's stock attractive given its efficient utilization of shareholder equity and positive analyst outlook.
📈 BDX trades at $155.92 with a $42.96 billion market cap.
🎯 Analysts project 14% upside to an average target of $177.75.
💵 Dividend yield stands at 2.69% with EPS of $5.72.
📈 Becton, Dickinson and Company (BDX) trades at $155.92 with a market cap of $42.96 billion in the healthcare sector.
🎯 Analysts project a 14% upside potential with an average target price of $177.75 based on current valuation metrics.
💰 The company reports robust free cash flow exceeding $4.5 billion, supporting operations and future ventures.
📊 BDX exhibits a forward P/E ratio of 11.64 and revenue growth rate of 5.20%, indicating strong financial performance.
💵 Investors receive a dividend yield of 2.69% with an EPS of $5.72 and a return on equity of 6.67%.
📉 Analyst sentiment is positive with six buy ratings, eight hold ratings, and no sell ratings currently active.
📈 Technical analysis shows the stock trading above its 50-day moving average with an RSI of 55.75 indicating neutral momentum.
🤝 BDX's strategic collaboration with ChemoGLO highlights a commitment to enhancing safety measures in healthcare settings.
🔮 The target price range spans from $150.00 to $225.00, offering various market scenarios for investors.
Bullish Signals
Potential upside of 14% with analyst target price of $177.75.
Forward P/E ratio of 11.64 indicates relative undervaluation.
Revenue growth rate of 5.20% sustains financial performance.
Robust free cash flow exceeds $4.5 billion.
Six buy and eight hold ratings show analyst confidence.
Bullish Signals
BDX exhibits a potential upside of 14% with an average analyst target price of $177.75, suggesting growth-focused investors may find value.
The company's forward P/E ratio of 11.64 indicates it is relatively undervalued compared to industry peers.
BDX demonstrates a solid revenue growth rate of 5.20%, underscoring its capability to sustain financial performance in the competitive medical supplies industry.
Robust free cash flow of over $4.5 billion reflects strong cash generation capacity, critical for sustaining operations and funding new ventures.
Analyst sentiment is largely positive with six buy ratings and eight hold ratings, indicating confidence in long-term growth prospects.
The stock is trading above its 50-day moving average of $148.23, suggesting a bullish trend may be forming.
Strategic collaboration with ChemoGLO underscores the company's commitment to innovation and enhancing safety measures within healthcare settings.
On June 12, Bank of America (BofA) lowered its price target for Becton, Dickinson and Company (NYSE: BDX) from $177 to $170 while maintaining a Neutral rating. The analyst cited continued lower utilization within the healthcare sector as a primary concern, leading to a more cautious outlook for 2027 estimates specifically for medtech companies.
BofA's analysis suggests that current valuations for BDX and similar peers already reflect significant risks related to utilization trends. Additionally, the firm expects inflation to persist as a major headwind in 2027, which could constrain margin expansion across the broader medical technology industry.
Consequently, Bank of America has reduced its 2027 earnings estimates for several large-cap companies in its coverage universe that face exposure to both utilization pressures and inflation. BDX is described as a global leader developing and selling medical supplies, devices, laboratory equipment, and diagnostic products used by various healthcare professionals.
📉 Bank of America cut BDX price target from $177 to $170 on June 12.
⚖️ Analyst maintained Neutral rating despite the price target reduction.
Becton Dickinson and Co. (BDX) reported fiscal second-quarter results that surpassed Wall Street expectations, driven by strong performance in its medical device manufacturing sector. The company posted a net profit of $277 million, translating to 94 cents per share on a GAAP basis. When adjusted for non-recurring costs, earnings reached $3.19 per share, significantly beating the average analyst estimate of $3.04 per share provided by Zacks Investment Research.
Revenue for the quarter totaled $4.91 billion, also exceeding the consensus forecast of $4.84 billion from seven surveyed analysts. This financial strength supports the company's full-year earnings guidance, which projects a range between $12.75 and $12.85 per share. Despite these solid operational results, BDX shares have underperformed the broader market, dropping roughly 5% over the last 12 months while the S&P 500 index has gained 11% since the beginning of the year.
📈 Q2 net income hit $277 million or 94 cents per share.
📊 Adjusted earnings of $3.19 beat the $3.04 analyst average.
💰 Revenue reached $4.91 billion, surpassing the $4.84 forecast.
🔮 Full-year guidance ranges from $12.75 to $12.85 per share.
📉 Stock declined 5% over the last 12 months.
📈 Becton Dickinson reported fiscal Q2 net income of $277 million, or 94 cents per share.
📊 Adjusted earnings for non-recurring costs were $3.19 per share, beating the $3.04 analyst average.
💰 Revenue reached $4.91 billion, surpassing the Street forecast of $4.84 billion.
🔮 The company provides full-year earnings guidance ranging from $12.75 to $12.85 per share.
📉 BDX stock has declined approximately 5% over the last 12 months, underperforming the S&P 500's 11% gain.
🏥 The medical device manufacturer is based in Franklin Lakes, New Jersey.
Bullish Signals
Beat EPS estimate with $3.19 adjusted earnings.
Revenue hit $4.91B, surpassing the $4.84B forecast.
Guidance set for full-year EPS between $12.75-$12.85.
Becton, Dickinson and Company (NYSE:BDX) saw mixed institutional activity in the fourth quarter, highlighted by Corient Private Wealth LLC reducing its stake by 14.7% to 85,346 shares. Conversely, Auto Owners Insurance Co significantly increased its position by over 22 million shares, while HSBC Holdings and other funds also boosted their holdings. The company maintains a high institutional ownership level of 86.97%, indicating strong continued interest from major investors despite some profit-taking.
Financially, BDX reported solid quarterly results with revenue of $4.71 billion, beating consensus estimates by $0.04 billion. The company posted earnings per share (EPS) of $2.90, surpassing analyst expectations of $2.77, and achieved a net margin of 5.33%. Revenue grew 5.2% year-over-year, demonstrating resilient demand for the medical instruments supplier's products across its diverse portfolio.
Analyst sentiment remains cautiously positive with an average price target of $181.00, though recent targets have been adjusted by major firms like Goldman Sachs and Bank of America. The stock trades at a PE ratio of 36.55 and offers a dividend yield of 2.9%, paying out slightly more than its earnings. Recent insider sales by CEO Thomas E. Polen, Jr. and EVP Michael David Garrison were executed under pre-arranged trading plans, which are standard procedures but noted in the market.
📉 Corient Private Wealth reduced BDX stake by 14.7% to $16.585 million.
📈 Auto Owners Insurance increased stake by 22,225.2% to $790 million.
💰 Q4 revenue hit $4.71 billion, beating estimates with 5.2% growth.
📊 EPS reached $2.90, topping consensus by $0.13.
🎯 Analysts hold average rating; Goldman Sachs lowered target to $150.
📉 Corient Private Wealth LLC reduced its BDX position by 14.7% to 85,346 shares worth $16.585 million during Q4.
📈 Auto Owners Insurance Co massively increased its stake by 22,225.2%, now holding over 40.7 million shares valued at $790 million.
💰 BDX reported Q4 revenue of $4.71 billion, beating analyst estimates and growing 5.2% year-over-year.
📊 The company posted EPS of $2.90, topping the consensus estimate of $2.77 by $0.13.
🎯 Analysts maintain an average 'Hold' rating with a price target of $181.00, though Goldman Sachs lowered its target to $150.
💵 BDX announced a quarterly dividend of $1.05 per share, payable on June 30th with a yield of 2.9%.
📉 The stock trades at a PE ratio of 36.55 and has a market capitalization of $39.79 billion.
👔 CEO Thomas E. Polen, Jr. sold 2,764 shares under a Rule 10b5-1 plan, reducing his ownership by 2.45%.
🏥 BDX operates in medical devices, life sciences research tools, and interventional technologies with global reach.
📉 The stock's 50-day moving average is $148.40 while the 200-day average sits at $171.47.
On June 6, 2026, Becton, Dickinson and Company (NYSE: BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep and FREPP skin preparation applicators due to potential fungal contamination by Aspergillus penicillioides. The affected lots, identified as 4032183 and 4073005, were distributed between March and June 2024 to hospitals and suppliers. While no adverse events have been reported yet, the company advises immediate cessation of use and destruction of the products, with replacements intended to be provided.
In financial news, Bank of America lowered its price target on BDX from $177 to $170 on June 12, 2026, while maintaining a Neutral rating. The analyst cited a lower utilization environment and increased inflation headwinds for 2027 as reasons for adopting a more conservative outlook on medtech companies, specifically reducing 2027 estimates across large-cap coverage to account for potential margin compression risks.
Jim Cramer expressed confidence in the stock earlier in June, noting that BDX is selling at the lowest level he has ever seen and suggesting investors buy while waiting to see if it oversells further. Despite these mixed signals regarding valuation and sentiment, the article concludes with promotional content for an investment newsletter rather than substantive analysis of the company's broader financial health or strategic position.
🦠 BD recalls ChloraPrep lots 4032183/4073005 due to Aspergillus contamination.
💬 Jim Cramer advises buying BDX at historic low levels in June.
🦠 Becton, Dickinson and Company (BDX) issued a voluntary recall on June 6, 2026, for specific lots of ChloraPrep and FREPP skin preparation applicators due to potential fungal contamination.
📅 The recalled products, identified by lot numbers 4032183 and 4073005, were distributed to hospitals and suppliers between March and June 2024.
⚠️ The contamination involves Aspergillus penicillioides, which poses severe risks including systemic infection, sepsis, and surgical complications, though no adverse events have been reported yet.
📉 Bank of America lowered its price target on BDX from $177 to $170 on June 12, 2026, citing lower utilization environments and inflation headwinds for 2027.
📊 The analyst firm reduced 2027 estimates across its large-cap medtech coverage to account for potential margin compression risks in the sector.
💬 Jim Cramer expressed confidence in BDX earlier in June, stating the stock is selling at the lowest level he has ever seen and advising investors to buy while waiting for further price drops.
Bullish Signals
Jim Cramer sees BDX as undervalued at lowest levels.
Company will replace recalled products to mitigate supply risks.
Risk Factors
Bank of America cut target from $177 to $170 citing inflation.
Skin prep recall poses operational and reputational risk from fungus.
Bullish Signals
Jim Cramer views BDX as undervalued, noting it is selling at the lowest level he has ever seen.
The company intends to provide replacements for the recalled products, mitigating long-term supply chain disruption risks.
Risk Factors
Bank of America lowered its price target from $177 to $170 due to concerns over lower utilization environments and inflation headwinds.
The analyst firm reduced 2027 estimates across large-cap medtech coverage, signaling sector-wide margin compression risks.
A voluntary recall for specific lots of skin preparation products poses a direct operational and reputational risk due to potential fungal contamination.
Becton Dickinson (BDX) faces a cautious outlook as Bank of America recently lowered its price target from $177 to $170 and maintained a Neutral rating. The analyst cited a softer utilization environment and inflation risks for the wider medtech sector in 2027 as primary drivers for the adjustment.
Market consensus remains mixed, with MarketBeat data showing an average target price of $140.37 based on 16 Wall Street analysts. The current split includes seven Buy, eight Hold, and one Sell recommendation, resulting in an overall 'Hold' consensus rating that reflects divergent views on growth versus margin pressure.
Shares of the NYSE-listed medical device group are trading at $145.43 as of June 23, 2026, which is approximately 49% below its all-time high of $287.32 reached in July 2023. The company generates significant revenue from medical-surgical products like syringes and the BD Venflon peripheral IV catheter line used globally for vascular access procedures.
Despite being part of the S&P 500 healthcare cohort alongside peers like Medtronic, BDX trades materially below large-cap medtech averages on valuation metrics. The stock recently experienced a 2.78% intraday move to $144.62, highlighting ongoing volatility and investor scrutiny regarding sector-wide headwinds.
📉 Bank of America lowers Becton Dickinson target to $170 with Neutral rating.
⚠️ Analysts warn of softer utilization and inflation risks for the medtech sector.
📊 MarketBeat consensus average price is $140.37 with seven Buy ratings.
💰 Shares closed at $145.43 on June 23, 2026, with a $42.5B market cap.
📉 Stock trades 49% below its July 2023 all-time high of $287.32.
📉 Bank of America lowered its Becton Dickinson price target from $177 to $170 while reiterating a Neutral rating.
⚠️ Analysts cited a softer utilization environment and inflation risks for 2027 as key concerns for the medtech sector.
📊 MarketBeat consensus data shows an average target price of $140.37 with a split of seven Buy, eight Hold, and one Sell ratings.
💰 Becton Dickinson shares closed at $145.43 on June 23, 2026, representing a market cap of $42.5 billion.
📉 The stock is currently trading approximately 49% below its all-time high of $287.32 reached in July 2023.
🏥 The company generates revenue from medical-surgical products including syringes, needles, and the BD Venflon peripheral IV catheter line.
📈 BDX is listed on the NYSE and is a component of the S&P 500 healthcare sector alongside peers like Medtronic.
🔄 Recent intraday trading saw a 2.78% move to $144.62 at 15:04 Eastern time on June 22, 2026.
Bullish Signals
BDX is an S&P 500 healthcare leader in global vascular access.
Strong revenue from worldwide syringe, needle, and infusion systems.
Risk Factors
Bank of America lowered price target due to softer utilization.
Inflation risks threaten wider medtech sector by 2027.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)